BioCryst Pharmaceuticals (BCRX) to Announce Quarterly Earnings on Wednesday

BioCryst Pharmaceuticals (NASDAQ:BCRX) is projected to issue its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect BioCryst Pharmaceuticals to post earnings of $0.14 per share and revenue of $183.2820 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:30 AM ET.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing the consensus estimate of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The firm had revenue of $156.41 million during the quarter, compared to analysts’ expectations of $151.12 million. During the same period in the previous year, the firm earned $0.20 earnings per share. The firm’s quarterly revenue was up 7.5% compared to the same quarter last year. On average, analysts expect BioCryst Pharmaceuticals to post $-3 EPS for the current fiscal year and $1 EPS for the next fiscal year.

BioCryst Pharmaceuticals Stock Up 1.7%

NASDAQ:BCRX opened at $9.74 on Wednesday. The firm has a market capitalization of $2.48 billion, a P/E ratio of -5.47 and a beta of 0.55. The company has a fifty day moving average of $9.25 and a 200 day moving average of $8.60. BioCryst Pharmaceuticals has a 52 week low of $6.00 and a 52 week high of $11.22.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Cantor Fitzgerald raised their target price on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 30th. Wall Street Zen cut BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Royal Bank Of Canada boosted their target price on BioCryst Pharmaceuticals from $13.00 to $14.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Needham & Company LLC dropped their price target on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Eight investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $20.80.

Institutional Trading of BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada grew its holdings in shares of BioCryst Pharmaceuticals by 2.4% during the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after acquiring an additional 1,458 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of BioCryst Pharmaceuticals by 6.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock valued at $1,019,000 after purchasing an additional 8,517 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 49.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock valued at $14,490,000 after purchasing an additional 640,704 shares during the period. Caxton Associates LLP purchased a new position in shares of BioCryst Pharmaceuticals in the 1st quarter valued at approximately $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of BioCryst Pharmaceuticals by 11.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock valued at $3,363,000 after purchasing an additional 47,355 shares in the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.